Ten Years of Hematopoietic Stem Cell Transplantation in Patients with Light Chain Amyloidosis: Real World Data from a Health Center in Latin America

GISELA BENDELMAN; BRULC, ERIKA B.; ADELA AGUIRRE; ELSA MERCEDES NUCIFORA; ET AL; MARIA POSADLOURDES POSADAS MARTINEZ

BLOOD, THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY - ONLINE

Elsevier

Año: 2023

1528-0020

Content MenuCloseDisclosures652.MULTIPLE MYELOMA: CLINICAL AND EPIDEMIOLOGICAL| NOVEMBER 28, 2023Ten Years of Hematopoietic Stem Cell Transplantation in Patients with Light Chain Amyloidosis: Real World Data from a Health Center in Latin AmericaGisela Bendelman, Erika Barbara Brulc, Maria Adela Aguirre, Elsa Mercedes Nucifora, María Agustina Marco, Maria Lourdes Posadas, Jorge Arbelbide, Valeria Ziegler, Marcelina CarreteroCrossmark: Check for UpdatesBlood (2023) 142 (Supplement 1): 6697.https://doi.org/10.1182/blood-2023-188895Split-ScreenShare IconShare Tools IconTools Background: Autologous stem cell transplantation (ASCT) is an effective treatment for patients with AL amyloidosis. In recent years, due to the advent of daratumumab-based regimens that achieve fast, deep, and long-lasting hematological responses, the role of ASCT and its optimal timing have been put in discussion. Access to ASCT in Latin America is difficult and specialized transplant centers are scarce, as is access to daratumumab-based chemotherapy regimens.Objectives: To describe the characteristics and evolution of patients with AL amyloidosis who received an autologous stem cell transplantation (ASCT) estimating organic response, overall and progression-free survival. To compare the evolution between patients initially eligible for transplantation and those who were not.